NEO

NeoGenomics, Inc. (NASDAQ:NEO) is a specialized cancer diagnostic testing company founded in 2001 and headquartered in Fort Myers, Florida. The company went public in 2004 and has since evolved into one of the leading providers of cancer-focused laboratory testing services in the United States. NeoGenomics operates a network of testing laboratories across the U.S., Europe, and Asia, serving hospitals, pathologists, oncologists, and pharmaceutical companies. The company has undergone significant strategic transformation in recent years, focusing on advanced genomic testing technologies and expanding its commercial presence in community oncology markets.